Favrille wins fast-track designation for cancer drug Favld
Favrille has won the FDA's fast-track designation for Favld, a treatment for follicular B-cell non-Hodgkin's lymphoma following Rituxan. An ongoing Phase III trial of Favld should produce data on secondary endpoints late this year while primary endpoint data is expected in the second half of 2007. "This decision by the FDA has the potential to save us valuable time in the regulatory approval process, and also serves as an important acknowledgment of the potential for FavId in the treatment of B-cell follicular NHL," John P. Longenecker, Ph.D., CEO of Favrille.
- read this AP report for more information
More stories about Phase III FDA Rituxan non-Hodgkin's lymphoma Regulators second half lymphoma Fast Track designation
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
